Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Apherese ForschungsInstitut – AFI’s post on LinkedIn, adding:
”Lp(a) does not act alone to help facilitate potentially life-threatening occlusive atheromas. Other factors, such as NETosis dysfunction and poor NET clearance, are likely at play, increasing the risk of CVD, heart failure, MI, and strokes.
Here are two other extracorporeal methods that target elevated extracellular chromatin/NETs that I believe should be trialed for potentially reversing diet and drug-refractory atherogenesis. They are simpler to perform and could be more efficacious than H.E.L.P. apheresis and other extracorporeal methods of lipid lowering.
A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation.
More research linking NETosis dysfunction to atherosclerosis progression and atheroma development can be found
Quoting Apherese ForschungsInstitut – AFI’s post:
”Elevated Lipoprotein(a) is a major, genetically determined driver of cardiovascular risk, yet it remains largely untouched by traditional lifestyle changes and statins.
A recent review in the European Heart Journal titled ‘Lipoprotein(a)-lowering therapies: a promising future’ highlights the evolving landscape of treatment.
At the Apherese Forschungsinstitut, we closely follow these developments. Phase III trials of RNA-based therapies specifically targeting Lp(a) are currently underway. Until these new drugs reach the market and prove long-term outcomes, Lipoprotein Apheresis continues to be the life-saving ‘gold standard’ for patients with extreme Lp(a) elevation and progressive ASCVD.
In the current therapeutic landscape, Lipoprotein Apheresis remains the only established and highly effective method to significantly reduce Lp(a) levels and mitigate cardiovascular events in high-risk patients.”
Title: Lipoprotein(a)-lowering therapies: a promising future
Authors: Jingwen Zhang, Ann Marie Navar, Lale Tokgozoglu
Read the Full Article on Apherese ForschungsInstitut – AFI
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL